The UK’s National Health Service will pay 25 percent more for new, patented U.S. medicines under the terms of a new trade agreement between the two nations.
The deal is the latest in a series of agreements in which the United States has leveraged tariffs to secure concessions on prescription drug prices. This is the first deal reached with a nation rather than with pharmaceutical manufacturers.
In return for this concession, the United States will forego tariffs on UK-made pharmaceuticals, pharmaceutical ingredients, and medical technology, as well as refrain from further pharmaceutical price negotiations during U.S. President Donald Trump’s term….
UK Agrees to Pay More for US Medicines After Trade Negotiations
